Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Ann Hematol. 2019 Jul;98(7):1733-1742. doi: 10.1007/s00277-019-03698-8. Epub 2019 May 3.
Hepatic sinusoidal obstruction syndrome (SOS) has been rarely studied after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective multicentre study on patients with SOS after allo-HSCT in China. The incidence, risk factors, and outcomes were compared between HID HSCT and matched related donor (MRD) HSCT. SOS developed in 0.4% of patients (HIDs: 0.4%, MRDs: 0.5%, p = 0.952) at a median time of 21.50 days (range, 1-55) after allo-HSCT (HIDs: 24 days, MRDs: 20 days, p = 0.316). For patients diagnosed with SOS, the 2-year cumulative incidence of relapse was 22.7% and 22.4% in patients receiving HID and MRD transplantation, respectively (p = 0.584). Overall survival (OS) at 2 year was 10.4% and 38.5% in the two groups (p = 0.113). The transplant-related mortality (TRM) at 100 days was 60.9% in the HID group and 38.5% in the MRD group (p = 0.178). According to the multivariate analyses, significant independent risk factors for the occurrence of SOS were delayed platelet engraftment (p = 0.007) and advanced disease status at the time of HSCT (p = 0.009). The outcomes of SOS after HID HSCT are similar to those after MRD HSCT.
肝窦阻塞综合征（SOS）在单倍体相合供者（HID）异基因造血干细胞移植（allo-HSCT）后很少被研究。我们在中国进行了一项回顾性多中心研究，研究对象为 allo-HSCT 后发生 SOS 的患者。比较了 HID HSCT 和匹配相关供者（MRD）HSCT 之间的发病率、危险因素和结局。SOS 在 allo-HSCT 后中位时间 21.50 天（范围 1-55）发生于 0.4%的患者（HIDs：0.4%，MRDs：0.5%，p=0.952）。对于诊断为 SOS 的患者，HID 和 MRD 移植患者的 2 年累积复发率分别为 22.7%和 22.4%（p=0.584）。两组患者 2 年总生存率（OS）分别为 10.4%和 38.5%（p=0.113）。HID 组 100 天移植相关死亡率（TRM）为 60.9%，MRD 组为 38.5%（p=0.178）。多因素分析显示，SOS 发生的独立危险因素有血小板延迟植入（p=0.007）和 HSCT 时疾病状态较晚（p=0.009）。HID HSCT 后 SOS 的结局与 MRD HSCT 后相似。
